Subatomic Physics research in Manitoba: Connecting the Canadian Prairies to the World
Dr Wouter Deconinck of the Department of Physics and Astronomy at the University of Manitoba, explores the initiatives which are pushing for inclusion of indigenous communities in its scientific research.
Gravitational wave science in Europe: Einstein Telescope and beyond
Professor Thomas Hertog at the KU Leuven discusses why black holes matter in this Gravitational wave science in Europe focus that includes comment on the Einstein Telescope and beyond.
SEA-TITAN Superconducting Power Take-Off
Luis García-Tabarés from CIEMAT, as Technical Manager in the H2020-funded SEA-TITAN, tells us what we need to know about the first of a kind superconducting direct drive power take off.
Epilepsy research: Improving infrastructure & management
Arun Swaminathan MD, Assistant Professor of Neurology and Epilepsy at the University of Nebraska Medical Center, considers the importance of improving infrastructure and management of epilepsy research.
Oceans: Delousing farmed salmon and trout
Here, we find out about delousing farmed salmon and trout, including the importance of fish welfare in this special oceans focus.
Nitric Oxide Formation Research
Dr Alan Schechter of the Molecular Medicine Branch at the National Institutes of Health in Bethesda, Maryland and his colleagues discuss research during the last two decades that has revealed a second major pathway for Nitric Oxide formation in mammals.
How valuable are randomised controlled trials in reproductive medicine?
Professor Darren Griffin reflects on how patients in fertility clinics should interpret the scientific evidence base when even the experts can’t seem to agree.
Bharat Biotech COVID vaccine shows 81% efficacy at Phase Three
The Bharat Biotech COVID vaccine, COVAXIN, appears to be 81% efficient against the virus in Phase Three of clinical trials.
The AstraZeneca vaccine is atleast 60% effective for people aged 70 and over
A study examining older people in the UK found that only one dose of the AstraZeneca vaccine is atleast 60% effective for people aged 70 and over.
Researchers investigate the genetics of eating disorders
An international research team have discovered that the genetics of eating disorders and some psychiatric disorders have some similarities, raising new questions about treatment for both.
Scientists find that elevated neutrophils can predict severe COVID and death
Researchers at Yale believe that blood tests could predict severe or critical COVID cases, because blood holds a series of interesting biological signals about a person.
FDA approves the Johnson & Johnson vaccine for use
The US Food and Drug Administration (FDA) approved the Johnson & Johnson vaccine, with an efficacy of 86%, as the next to be rolled out across the US.
The window for convalescent plasma donation is just under two months
New data suggests that before 60 days of COVID symptoms beginning is the best window for convalescent plasma donation - which is how antibodies were created in countless COVID-19 patients before vaccines.
1.17 million doses of the AstraZeneca vaccine could expire in Germany
Germans have only taken 270,986 AstraZeneca doses so far, leaving roughly 1.17 million doses in storage across the country - but these shots are due to expire in less than six months.
Horizon Europe: EU research & innovation
Mariya Gabriel, European Commissioner for Innovation, Research, Culture, Education and Youth, describes Horizon Europe and scaling up high-impact and breakthrough research & innovation.
REACT study: UK vaccine hesitancy is the highest in London
New data from the REACT study finds that 14% of the UK population have antibodies against COVID-19 now, but that vaccine hesitancy is currently highest in London.
Horizon Europe launches €619 million Starting Grants for researchers
The first Horizon Europe grants will be launched today (25 February), with Starting Grants for researchers worth €619 million available.
The Californian COVID mutation is more infectious
The Californian COVID mutation appears to be as infectious as the UK or South African mutations - but does it have the potential to be more deadly?
FDA reveals that Johnson & Johnson vaccine is 86% effective
New documents from the FDA show that the Johnson & Johnson vaccine appears to be 86% effective against COVID-19 - signalling that it will soon be approved in the US.
Targeted policy support for emerging biomedical innovations
Michael Morrison, Senior Researcher in Social Science at the University of Oxford, illustrates the importance of emerging biomedical innovations in the UK.
